Summary. Uterine samples were either rapidly frozen in liquid nitrogen or placed in Bouin's fixative. A commercial primary polyclonal antibody made in rabbits against human recombinant basic fibroblast growth factor (bFGF) was used. Western blot analysis indicated that the antibody was specific for bFGF and did not react with acidic FGF. The primary antibody was followed by either goat anti-rabbit immunoglobulin G (IgG) conjugated to the fluorescent phycobiliprotein tracer phycoerythrin or biotinylated goat anti-rabbit IgG and a biotin\p=n-\avidin\p=n-\peroxidase complex. Specificity controls using adjacent sections were carried out by (i) substituting normal rabbit sera for the primary antisera, (ii) omitting the primary antisera or (iii) extracting sections with NaCl (2 mol l \ m=-\ 1) prior to the immunochemical procedures. No binding of the antibody was observed with any of the specificity control sections. The connective tissue stroma and the basal lamina associated with uterine glandular and surface epithelial layers were positive for bFGF. Localization was not observed within surface or glandular epithelial cells. The basal lamina and endothelial cells associated with blood vessels within the uterus and the smooth muscle cells of the myometrium were positive for bFGF. There were no differences in uterine localization patterns or intensity during the oestrous cycle or after ovariectomy and steroid hormone supplementation. These studies demonstrate the specific localization of bFGF within the mouse uterus.
Introduction
Fìbroblast growth factors (FGF) constitute a family of structurally related, biologically active, peptides that have a strong affinity for heparin (Baird et al, 1986; Burgess & Maciag, 1989;  Klagsbrun, 1989; Rifkin & Moscatelli, 1989) . Basic fìbroblast growth factor (bFGF) is a single-chain, nonglycosylated, cationic polypeptide with molecular mass of about 18 kDa and pi (Shing et al, 1983 (Shing et al, , 1984 . Basic FGF was isolated from bovine pituitary (Gospodarowicz, 1974) and brain (Gospodarowicz et ai, 1978) and is mitogenic for a variety of cells derived from mesoderm and neuroectoderm including fibroblasts, endothelial cells and glial cells (Gospodarowicz, 1987) ; it is also a potent promoter of angiogenesis (Folkman & Klagsburn, 1987) and a strong stimulator of collagenase and plasminogen activator production (Sato & Rifkin, 1988; Buckley-Sturrock et al, 1989) .
These biological activities suggest that bFGF may potentially be a critical regulatory factor, which may modulate various physiological responses within the uterus, but there is little infor¬ mation concerning its presence within these tissues. Although heparin-binding growth factors have been purified and characterized from porcine (Brigstock et al, 1990 ) and bovine (Milner et al., 1989) uteri, the immunolocalization of specific members of the fìbroblast growth factor family within the uterus has not been previously reported.
The objective of this study was (i) to use light microscopy immunohistochemistry to localize bFGF specifically within the mouse uterus and (ii) to determine whether the localization of bFGF within the uterus is influenced by the (Rankin et ai, 1979) and deciduoma formation (Wordinger et ai, 1986) . The regimen included: 0-1 mg oestradiol on days 1-3, no treatment on days 4-5, 6-7 ng oestradiol and 1 0 mg progesterone on days 6-7 and 1 -0 mg progesterone on days 8-11. All hormones were given subcutaneously in 0-1 ml of corn oil at 09:00 h. Representative animals were killed by cervical dislocation on days 0, 3, 5, 7 and 11. Uterine horns were dissected and tissues prepared for immunohistochemical localization of bFGF.
Primary antisera
This experiment used two primary antibodies against bFGF: one (donated by Andrew Baird, Whittier Institute, La Jolla, CA, USA) is a polyclonal antibody raised against the 1-24 synthetic fragment of bovine bFGF in which the antigen sequence has only low homology with known FGF-like oncogene products and whose specificity has been reported (Gonzalez et ai, 1990 (Biomeda Corp., Forster City, CA, USA) for 1 h. After washing in PBS, FluorSave (Calbiochem, La Jolla, CA, USA), aqueous mounting medium was used to preserve fluorescent-stained tissue sections. All sections were subsequently examined with a Zeiss Photomicroscope III equipped for epifluorescence. Photomicrographs were recorded on T-Max p3200 professional film (Eastman Kodak Co., Rochester, NY, USA).
The choice of an immunoconjugate using the phycobiliprotein phycoerythrin (PE) was based on its higher sensi¬ tivity and the propensity for fluorescein to bind nonspecifically to surfaces (Oi et ai, 1982; Glazer& Stryer, 1984) . Our initial attempt to localize bFGF within uterine tissues using fluorescein-conjugated goat anti-rabbit IgG as the secondary antibody was unsuccessful because of high nonspecific staining of the conjugate (data not shown).
Immunoperoxidase localization of bFGF
The technique of Gonzalez et ai (1990) 
Results

Specificity of the immunohistochemical localization of bFGF
Western blot analysis indicated that the commercial antibody recognized only the 18kDa bFGF and did not crossreact with aFGF (Fig. 1) . The specificity of the technique was further assessed by (i) incubating tissue sections with goat anti-rabbit IgG conjugated to PE or biotin in the absence of the primary antisera, which examines the identification of nonspecific adsorption of the second antibody to the tissue sections; (ii) incubating tissue sections in pooled rabbit sera followed by goat anti-rabbit IgG-PE or biotinylated goat anti-rabbit IgG, which examines non¬ specific binding of IgG to the tissue sections; and (iii) extraction of tissue sections with 20mol NaCl 1_1 for 60 min at 37°C, which removes extracellular bFGF (Gonzalez et al, 1990 ). There was a lack of staining in all control sections examined. Nonspecific binding of avidin to mast-cell granules was not observed using the biotin-avidin-peroxidase complex. A previous report had indicated that avidin conjugated to peroxidase or fluorescein binds to mast-cell granules (Tharp et al, 1985) . 
Comparison of antibodies
The commerical antibody raised in rabbits against human recombinant bFGF and the donated antisera raised in rabbits against amino acids 1-24 of the synthetic fragment of bovine bFGF resulted in identical localization patterns in this study.
Immunohistochemical localization of bFGF in the uterus
Both immunofluorescent and immunoperoxidase localization techniques demonstrated the presence of bFGF within the uterus. Within the endometrium, the extracellular matrix was positive for bFGF localization (Fig. 2) . The basal laminae underlying the endometrial luminal (Fig. 4) and glandular (Fig. 5) epithelial cell layers were highly reactive, but the glandular and surface epithelial cells lacked bFGF. Both immunofluorescent (Fig. 2) and immunoperoxidase (Fig. 6) control slides (Fig. 3) were negative for immunolocalization of bFGF.
The basal laminae and endothelial cells associated with vascular elements throughout the uterus were reactive (Fig. 7) . Staining was also observed within the myofibrils of arteries (Figs 7 and 8) . Within the myometrium, the inner circular and outer longitudinal smooth-muscle layers were highly reactive (Figs 7 and 8 ). Control slides revealed no staining within any myometrial compo¬ nents (Figs 3 and 6) . The extracellular matrix of the perimetrium was also positive for bFGF as was the basal lamina associated with the mesothelial covering of the uterus.
Influence of the oestrous cycle on the immunolocalization of bFGF in the uterus Uterine tissue sections were examined for bFGF localization by the immunofluorescent tech¬ nique. Tissue samples were obtained at oestrus, dioestrus, metoestrus and proestrus. There was little if any variation in bFGF staining intensity or localization pattern within the uterus during the oestrous cycle. Basic FGF was localized in the extracellular matrices including the basal laminae and the smooth-muscle layers exhibited identical localization patterns to that described above.
Influence of ovariectomy and steroid hormone supplementation on the immunolocalization of bFGF in the uterus Uterine tissue sections were examined for bFGF localization by the immunofluorescent tech¬ nique. Tissue samples were examined on days 0, 3, 5, 7 and 11 after ovariectomy and steroid hormone supplementation. These days correspond to ovariectomy without hormone treatment (day 0), oestradiol alone (day 3), oestradiol and progesterone (day 5), and progesterone alone (days 7 and 11), respectively. There was little if any variation in the localization of bFGF after ovari¬ ectomy and steroid hormone supplementation; bFGF was localized in the extracellular matrices including the basal laminae and the smooth-muscle layers of the myometrium exhibited identical localization patterns to that described above.
Discussion
Basic FGF is a member of a family of polypeptides characterized by their wide distribution in tissues and their ability to modulate cell proliferation, differentiation and angiogenesis (see Baird et al, 1986; Gospodarowicz & Cheng, 1986; Burgess & Macaig, 1989;  Klagsbrun, 1989 for reviews). It has been suggested that bFGF is sequestered in a stabilized form within the extracellular matrix (Baird & Ling, 1987; Folkman et al, 1988; Vlodavsky et al, 1987; Baird & Walicke, 1989 . Our results are in agreement with this suggestion, since we demonstrated that the immunolocalization of bFGF within the uterus is within the extracellular matrix including the basal laminae associated with epithelial and endothelial cell layers. We demonstrated the localization of bFGF within smooth-muscle myofibrils associated with arteries and the myometrium. Although Brigstock et al. (1990) and Milner et al. (1989) characterized and purified heparin-binding growth factors from porcine and bovine uterus, the specific immunohistochemical localization of bFGF within the endometrium and myometrium of the uterus had not been reported.
The cell source and the mechanism by which bFGF reaches the uterine extracellular matrix is not known, since bFGF lacks a signal peptide (Abraham et al, 1986) . The bFGF produced by cells appears to remain cell associated or is deposited in the extracellular matrix by an unknown mechanism. Both basic and acidic FGF have a strong affinity for the anionic glycosaminoglycan, heparin (Shing et al, 1983 (Shing et al, , 1984 ), which appears to be a stabilizing factor that protects basic and acidic FGF from inactivation by acid and heat (Gospodarowicz & Cheng, 1986) and degradation by proteases (Sommer & Rifkin, 1989) . These extracellular heparin-like binding sites may be reservoirs that concentrate bFGF in the vicinity of potential target cells .
The ubiquity of fìbroblast growth factors in normal adult tissues that are neither growing nor undergoing angiogenesis or differentiation suggests that FGF activity must be highly regulated under normal physiological conditions. Shimasaki et al. (1988) reported that FGF mRNA was below the limits of detection in adrenal gland, spleen, heart, lung, kidney, liver, stomach, small intestine and large intestine, despite the high concentrations of FGF found in these tissues. This implies that the bFGF gene is transcribed neither constitutively nor in large amounts, but that its transcription may be induced intermittently when the extracellular storage of bFGF has been depleted. Little is known about the bio-availability of bFGF stored within the extracellular matrix or basal lamina. It is possible that bFGF is stored in the extracellular matrix in a bio-unavailable form and that the regulation of bFGF is at the level of its bio-availability rather than its synthesis (Baird & Ling, 1987) .
Although oestrogen has been studied extensively as a key regulator of uterine cell growth (Murphy & Ghahary, 1990) , it has been suggested that uterine growth factors may also mediate uterine responses (Brigstock et al, 1989; Pollard, 1990) . It is possible that the mitogenic effect attributed to oestrogens may be mediated via growth factors synthesized by the uterus in response to steroid hormones (Brigstock, 1991) . It has been reported that the uterine expression of insulin¬ like growth factors I and II (Murphy et al, 1987) and epidermal growth factor (Gonzalez et al, 1984; Di Augustine et al, 1988 ) is regulated by oestrogens.
Although Presta (1988) has shown that synthesis of bFGF in uterine adenocarcinoma cells was stimulated by oestradiol, no previous studies have examined the regulation of uterine FGF by steroidal hormones in animals. Our studies indicate that there was no influence of the stage of the oestrous cycle or ovariectomy followed by steroid hormone supplementation on bFGF localization in the uterine extracellular matrix. Although biologically active endogenous bFGF can be released from the extracellular matrix (Saksela & Rifkin, 1990) We are currently examining whether the localization of bFGF within the uterus is influenced by embryo invasion into the extracellular matrix and decidual cell formation.
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